- Home
- ARBE vs ZBIO Comparison
ARBE vs ZBIO Comparison
Compare ARBE & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBE
- ZBIO
- Stock Information
- Founded
- ARBE 2015
- ZBIO 2019
- Country
- ARBE Israel
- ZBIO United States
- Employees
- ARBE N/A
- ZBIO N/A
- Industry
- ARBE EDP Services
- ZBIO
- Sector
- ARBE Technology
- ZBIO
- Exchange
- ARBE Nasdaq
- ZBIO NYSE
- Market Cap
- ARBE 312.4M
- ZBIO 339.3M
- IPO Year
- ARBE N/A
- ZBIO 2024
- Fundamental
- Price
- ARBE $2.89
- ZBIO $8.40
- Analyst Decision
- ARBE Strong Buy
- ZBIO Strong Buy
- Analyst Count
- ARBE 2
- ZBIO 5
- Target Price
- ARBE $3.00
- ZBIO $31.75
- AVG Volume (30 Days)
- ARBE 19.2M
- ZBIO 371.9K
- Earning Date
- ARBE 03-06-2025
- ZBIO 02-16-2025
- Dividend Yield
- ARBE N/A
- ZBIO N/A
- EPS Growth
- ARBE N/A
- ZBIO N/A
- EPS
- ARBE N/A
- ZBIO N/A
- Revenue
- ARBE $1,016,000.00
- ZBIO N/A
- Revenue This Year
- ARBE $1.56
- ZBIO N/A
- Revenue Next Year
- ARBE $395.31
- ZBIO N/A
- P/E Ratio
- ARBE N/A
- ZBIO N/A
- Revenue Growth
- ARBE N/A
- ZBIO N/A
- 52 Week Low
- ARBE $1.40
- ZBIO $7.50
- 52 Week High
- ARBE $5.09
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- ARBE 54.73
- ZBIO N/A
- Support Level
- ARBE $2.70
- ZBIO N/A
- Resistance Level
- ARBE $3.29
- ZBIO N/A
- Average True Range (ATR)
- ARBE 0.66
- ZBIO 0.00
- MACD
- ARBE -0.01
- ZBIO 0.00
- Stochastic Oscillator
- ARBE 33.13
- ZBIO 0.00
About ARBE Arbe Robotics Ltd.
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, USA, and others.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.